TickerGuard
Buy Day today: Neutral (48) Mixed market breadth · no major macro event
GMAB

Genmab AS

Healthcare · Biotechnology

35.40$ +0.1% vs. previous close Closing price · As of: Sep 28, 2026

Statements

Income Statement

Genmab AS (GMAB) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q2 26), "Revenue" came in at 1,155 million USD. Tick rows to compare them in a chart.

All figures in millions of USD.

Tick rows to compare them in a chart (up to 4)

Income Statement GMAB
Line item Q3 23 Q4 23 Q1 24 Q2 24 Q3 24 Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 LTM
4,712 4,678 603 779 5,540 6,441 105 925 1,022 1,055 899 1,155 4,131
79 126 27 28 273 337 6.2 57 58 81 65 84 288
4,633 4,552 576 751 5,267 6,104 99 868 964 974 834 1,071 3,843
2,088 1,948 335 361 2,283 2,664 53 364 357 524 442 459 1,782
839 934 857 894 865 1,249 126 144 148 208 166 205 727
2,948 2,882 460 515 3,165 3,944 71 508 505 732 608 664 2,509
1,685 1,670 116 236 2,102 2,160 28 360 459 242 226 407 1,334
8.0 6.0 4.0 19 18 54 0.7 9.0 3.0 44 112 110 269
2,670 926 249 307 1,719 3,602 36 423 482 55 74 295 906
566 286 57 104 453 -243 7.2 87 81 24 21 -8.0 118
2,104 640 192 203 1,266 3,845 29 336 401 31 53 303 788
2,764 992 266 324 2,204 2,355 39 448 503 99 187 431 1,219

LTM = last twelve months (sum of the four most recent quarters).

Data as of: September 28, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?